The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes
Abstract
OBJECTIVE: To define the threshold for excess glucose variability (GV), one of the main features of dysglycemia in diabetes. RESEARCH DESIGN AND METHODS: A total of 376 persons with diabetes investigated at the University Hospital of Montpellier (Montpellier, France) underwent continuous glucose monitoring. Participants with type 2 diabetes were divided into several groups—groups 1, 2a, 2b, and 3 (n = 82, 28, 65, and 79, respectively)—according to treatment: 1) diet and/or insulin sensitizers alone; 2) oral therapy including an insulinotropic agent, dipeptidyl peptidase 4 inhibitors (group 2a) or sulfonylureas (group 2b); or 3) insulin. Group 4 included 122 persons with type 1 diabetes. Percentage coefficient of variation for glucose (%CV = [(SD of glucose)/(mean glucose)] × 100) and frequencies of hypoglycemia (interstitial glucose <56 mg/dL [3.1 mmol/L]) were computed. RESULTS: Percentages of CV (median [interquartile range]; %) increased significantly (P < 0.0001) from group 1 (18.1 [15.2–23.9]) to group 4 (37.2 [31.0–42.3]). In group 1, the upper limit of %CV, which served as reference for defining excess GV, was 36%. Percentages of patients with %CVs above this threshold in groups 2a, 2b, 3, and 4 were 0, 12.3, 19.0, and 55.7%, respectively. Hypoglycemia was more frequent in group 2b (P < 0.01) and groups 3 and 4 (P < 0.0001) when subjects with a %CV >36% were compared with those with %CV ≤36%. CONCLUSIONS: A %CV of 36% appears to be a suitable threshold to distinguish between stable and unstable glycemia in diabetes because beyond this limit, the frequency of hypoglycemia is significantly increased, especially in insulin-treated subjects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a mixed population of people with T2D, the incidence of hypoglycemic events was three to six times greater in patients with a within-day CV of more than 36% compared with a CV less than 36%, irrespective of the type of treatment with oral diabetes drugs or insulin.47”
From Glycemic variability and cardiovascular disease in patients with type 2 diabetes (2021) · cites this paper as [47]
Citations
Cites
Baltosser, W. H., & Zar, J. H. (1996) · Ecology · doi:10.2307/2265725 · Cited by 35,166
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Biostatistical Analysis (2nd ed.).
Breen, T. J., & Zar, J. H. (1986) · Journal of the American Statistical Association · doi:10.2307/2289268 · Cited by 5,792
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444
Self-citationDefining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414266 · Cited by 668 · cited 1×
“in the pathogenesis of all related complications from diabetes, both in type 1 (1,2) and type 2 diabetes (3,4).”
BackgroundKovatchev, B. P., Cox, D. J., Gonder-Frederick, L. A., Young-Hyman, D. L., Schlundt, D. G., & Clarke, W. L. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1870 · Cited by 309
Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does!
Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc14-2898 · Cited by 291
Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes
Kovatchev, B. P., & Cobelli, C. (2016) · Diabetes Care · doi:10.2337/dc15-2035 · Cited by 276
Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia
Cryer, P. E. (2014) · Diabetes · doi:10.2337/db14-0059 · Cited by 241
Glucose Variability: Where It Is Important and How to Measure It
DeVries, J. H. (2013) · Diabetes · doi:10.2337/db12-1610 · Cited by 236
New and Improved Methods to Characterize Glycemic Variability Using Continuous Glucose Monitoring
Rodbard, D. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0015 · Cited by 235
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s008 · Cited by 220
Kilpatrick, E. S., Rigby, A. S., Goode, K. M., & Atkin, S. L. (2007) · Diabetologia · doi:10.1007/s00125-007-0820-z · Cited by 213
Monsod, T. P., Flanagan, D., Rife, F., Saenz, R., Caprio, S., Sherwin, R. S., & Tamborlane, W. V. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.889 · Cited by 173
The Contribution of Glucose Variability to Asymptomatic Hypoglycemia in Persons with Type 2 Diabetes
Monnier, L., Wojtusciszyn, A., Colette, C., & Owens, D. R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0049 · Cited by 172
Self-citationBergenstal, R. M. (2015) · Diabetes Care · doi:10.2337/dc15-0099 · Cited by 140
The FLAT-SUGAR Trial Investigators (2016) · Diabetes Care · doi:10.2337/dc15-2782 · Cited by 135
Glycemic Variability: It's Not Just About A1C Anymore!
Hirsch, I. B. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.780 · Cited by 130
Prediction of Severe Hypoglycemia
Cox, D. J., Gonder-Frederick, L., Ritterband, L., Clarke, W., & Kovatchev, B. P. (2007) · Diabetes Care · doi:10.2337/dc06-1386 · Cited by 129
Clinical Interpretation of Indices of Quality of Glycemic Control and Glycemic Variability
Rodbard, D. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2310 · Cited by 127
Guerci, B., Floriot, M., Böhme, P., Durain, D., Bénichou, M., Jellimann, S., & Drouin, P. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.582 · Cited by 126
Rodbard, D. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0062 · Cited by 88
Monnier, L., Colette, C., & Owens, D. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.014 · Cited by 88
Self-citationThe Assessment of Glycemic Variability and Its Impact on Diabetes-Related Complications: An Overview
Weber, C., & Schnell, O. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0043 · Cited by 73
Glycemic Variability in Nondiabetic Morbidly Obese Persons
Salkind, S. J., Huizenga, R., Fonda, S. J., Walker, M. S., & Vigersky, R. A. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814537039 · Cited by 54
Fabris, C., Facchinetti, A., Sparacino, G., Zanon, M., Guerra, S., Maran, A., & Cobelli, C. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0252 · Cited by 48
Kohnert, K., Heinke, P., Fritzsche, G., Vogt, L., Augstein, P., & Salzsieder, E. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0303 · Cited by 47
Evaluation of the Menarini–Arkray HA 8140 hemoglobin A1c analyzer
John, W. G., Braconnier, F., Miedema, K., Aulesa, C., & Piras, G. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.6.968 · Cited by 42
The FLAT-SUGAR Trial Investigators (2015) · Diabetes Care · doi:10.2337/dc14-2689 · Cited by 38
Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9325-8 · Cited by 29
Self-citationLuijf, Y. M., Avogaro, A., Benesch, C., Bruttomesso, D., Cobelli, C., Ellmerer, M., Heinemann, L., Mader, J. K., & DeVries, J. H. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600514 · Cited by 25
Flagged first, then by citations
Research works printed but not linked: 1
- Midyett, 2016, Assessment of glucose variability by professional flash glucose monitoring across therapy groups for type 2 diabetes, Diabetes, 65, A222
Cited by
Sorted by citations
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
“*Some studies suggest that lower %CV targets (,33%) provide additional protection against hypoglycemia for those receiving insulin or sulfonylureas (45,90,91).”
BackgroundInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Glycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588
Self-citationCappon, G., Vettoretti, M., Sparacino, G., & Facchinetti, A. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0121 · Cited by 477
Metadata
- Authors
- Monnier, L., Colette, C., Wojtusciszyn, A., Dejager, S., Renard, E., Molinari, N., & Owens, D. R.
- Affiliations
- Université de Montpellier (FR)
- Pitié-Salpêtrière Hospital (FR)
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital, University of Montpellier, Montpellier, France
- Swansea University (GB)
- Corresponding author
- Monnier, Louis
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-12-30
- Volume
- 40
- Issue
- 7
- Pages
- 832-838
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2566952971
- Cited by
- 390
- References
- 40
- Citations by year
- 2026: 25 · 2025: 41 · 2024: 45 · 2023: 39 · 2022: 48 · 2021: 53 · 2020: 44 · 2019: 44 · 2018: 33 · 2017: 17
- FWCI
- 31.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- glycemic variability, type 2 diabetes, type 1 diabetes, coefficient of variation, hypoglycemia, continuous glucose monitoring, insulin therapy, DPP-4 inhibitors, sulfonylureas, insulin sensitizers, glycemic stability, threshold
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Sulfonylurea Compounds, Treatment Outcome, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review